Chest:预测肺癌的慢性阻塞性肺疾病临床特征!

2018-02-14 xing.T MedSci原创

由此可见,COPD严重程度,包括气流阻塞、肺气肿和呼吸功能恶化都是肺癌的独立预测因素。这些危险因素应作为肺癌筛查生存获益的纳入标准和排除标准开展进一步研究。同时,需要进行研究来确定减少吸烟者呼吸功能恶化是否能降低肺癌风险。

肺癌是导致慢性阻塞性肺病(COPD)患者死亡和住院的主要原因,需要详细了解COPD的临床特征。近日,呼吸领域权威杂志chest上发表了一篇研究文章。该研究旨在确定有无COPD的吸烟者临床及影像学特点,这些特征是否与肺癌的发病风险增加有关。

研究人员对携带和未携带肺癌基因的COPD患者进行了一项巢式病例对照研究,这些患者年龄为45-80岁,至少抽烟10包每年。基线评估包括:肺活量、高分辨率胸部CT和呼吸问卷。八年的纵向随访确定新发的肺癌诊断。肺癌患者以1:4的比例匹配年龄、种族、性别、吸烟史相似的对照者。多因素logistic回归分析用于确定预测肺癌的临床特征。

与未来肺癌风险相关的临床特征包括:降低的FEV1/FVC(每减少10%的比值比(OR)为1.28,95%可信区间(CI)为1.12-1.46)、肺气肿的严重程度(OR为2.31,95%CI为1.41-3.86)、进入研究前的呼吸加重(每增加一次事件的OR为1.39,95%CI为1.04-1.85)。呼吸加重也与小细胞肺癌组织学类型相关(OR为3.57,95%CI为1.47-10)。

由此可见,COPD严重程度,包括气流阻塞、肺气肿和呼吸功能恶化都是肺癌的独立预测因素。这些危险因素应作为肺癌筛查生存获益的纳入标准和排除标准开展进一步研究。同时,需要进行研究来确定减少吸烟者呼吸功能恶化是否能降低肺癌风险。 

原始出处:

Laurie L. Carr,et al. Features of Chronic Obstructive Pulmonary Disease as Predictors of Lung Cancer.chest.2018. https://doi.org/10.1016/j.chest.2018.01.049

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1842877, encodeId=f8ef18428e7f9, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Wed May 16 06:01:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051062, encodeId=fb9b20510627b, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 19 21:01:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696801, encodeId=9d761696801ef, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat May 26 13:01:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929468, encodeId=0d8c19294685b, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Jan 28 09:01:00 CST 2019, time=2019-01-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1842877, encodeId=f8ef18428e7f9, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Wed May 16 06:01:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051062, encodeId=fb9b20510627b, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 19 21:01:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696801, encodeId=9d761696801ef, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat May 26 13:01:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929468, encodeId=0d8c19294685b, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Jan 28 09:01:00 CST 2019, time=2019-01-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1842877, encodeId=f8ef18428e7f9, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Wed May 16 06:01:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051062, encodeId=fb9b20510627b, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 19 21:01:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696801, encodeId=9d761696801ef, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat May 26 13:01:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929468, encodeId=0d8c19294685b, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Jan 28 09:01:00 CST 2019, time=2019-01-28, status=1, ipAttribution=)]
    2018-05-26 tomyang96
  4. [GetPortalCommentsPageByObjectIdResponse(id=1842877, encodeId=f8ef18428e7f9, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Wed May 16 06:01:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051062, encodeId=fb9b20510627b, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 19 21:01:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696801, encodeId=9d761696801ef, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat May 26 13:01:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929468, encodeId=0d8c19294685b, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Jan 28 09:01:00 CST 2019, time=2019-01-28, status=1, ipAttribution=)]
    2019-01-28 Smile2680

相关资讯

Eur Heart J-Card Img:肺动脉硬化指数预测肺血管疾病患儿疾病进展和死亡

由此可见,在PVD患儿中,通过IVUS评估的PA-硬化指数可以预测长期随访的PAH和死亡率。特别是对于血流动力学稳定的患者,评估内在的PA硬化可能会提高疾病进展和生存的预后。

Int J Cardiol:肝纤维化标志物IV型胶原蛋白7S结构域在肺动脉高压患者中的应用!

由此可见,血清P4NP 7S与PH患者较高的中心静脉压、右侧容积超负荷和死亡率有关。

SCI REP:晚期糖基化终末产物受体与ARDS预测!

由此可见,这些研究结果表明高危的ICU患者中,较高的血浆sRAGE可能识别那些更可能发展为ARDS的个体。

Clin Otolaryngol:通过机器学习模型来预测突发性感官听力损失患者的听力结果

突发性感官听力损失(SSHL)是一种多因子障碍疾病且伴随着高度的异质性,因此,结果具有很大的不同。最近,有研究人员基于4种SSHL机器学习模型来开发预测模型,从而鉴定最好的模型来用于临床。研究包括了1220名SSHL患者,时间为2008年6月到2015年12月。研究发现,在包括149个变量的原生数据测试中,深度信念网络(DBN)模型具有最好的预测能力,预测准确性为77.58%,AUC为0.84。然

Ann Intern Med:疑似感染患者快速序贯器官衰竭评估预测死亡的准确性!

由此可见,qSOFA对短期死亡的敏感性低,特异性适中。SIRS标准的敏感性优于qSOFA,支持其用于筛查患者和作为开始治疗的指征。

ATVB:MiR-146a调节可预测房颤患者不良心血管事件的NET形成!

由此可见,NE活性可以为AF患者提供新的ACE预后信息。这些发现提供了miR-146a在嗜中性粒细胞胞外陷阱产生和心血管风险中发挥潜在作用的证据。